| The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients J Hallin, LD Engstrom, L Hargis, A Calinisan, R Aranda, DM Briere, ... Cancer discovery 10 (1), 54-71, 2020 | 1067 | 2020 |
| Acquired Resistance to KRASG12C Inhibition in Cancer MM Awad, S Liu, II Rybkin, KC Arbour, J Dilly, VW Zhu, ML Johnson, ... New England Journal of Medicine 384 (25), 2382-2393, 2021 | 674 | 2021 |
| Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3 … TW Johnson, PF Richardson, S Bailey, A Brooun, BJ Burke, MR Collins, ... Journal of medicinal chemistry 57 (11), 4720-4744, 2014 | 578 | 2014 |
| PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models HY Zou, L Friboulet, DP Kodack, LD Engstrom, Q Li, M West, RW Tang, ... Cancer cell 28 (1), 70-81, 2015 | 485 | 2015 |
| PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations HY Zou, Q Li, LD Engstrom, M West, V Appleman, KA Wong, M McTigue, ... Proceedings of the National Academy of Sciences 112 (11), 3493-3498, 2015 | 275 | 2015 |
| Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor J Hallin, V Bowcut, A Calinisan, DM Briere, L Hargis, LD Engstrom, ... Nature medicine 28 (10), 2171-2182, 2022 | 227 | 2022 |
| The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy D Briere, N Sudhakar, DM Woods, J Hallin, LD Engstrom, R Aranda, ... Cancer Immunology, Immunotherapy 67, 381-392, 2018 | 140 | 2018 |
| Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to … LD Engstrom, R Aranda, M Lee, EA Tovar, CJ Essenburg, Z Madaj, ... Clinical Cancer Research 23 (21), 6661-6672, 2017 | 133 | 2017 |
| Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib Q Huang, TW Johnson, S Bailey, A Brooun, KD Bunker, BJ Burke, ... Journal of medicinal chemistry 57 (4), 1170-1187, 2014 | 129 | 2014 |
| The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy DM Briere, S Li, A Calinisan, N Sudhakar, R Aranda, L Hargis, DH Peng, ... Molecular cancer therapeutics 20 (6), 975-985, 2021 | 106 | 2021 |
| Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor HY Zou, Q Li, JH Lee, ME Arango, K Burgess, M Qiu, LD Engstrom, ... Molecular cancer therapeutics 11 (4), 1036-1047, 2012 | 87 | 2012 |
| Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers CR Smith, R Aranda, TP Bobinski, DM Briere, AC Burns, JG Christensen, ... Journal of Medicinal Chemistry 65 (3), 1749-1766, 2022 | 72 | 2022 |
| Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells. WDS Taj MM, Tawil RJ, Engstrom LD, Zeng Z, Hwang C, Sanda MG Prostate 47 (3), 194-204, 2001 | 56 | 2001 |
| A novel chromosomal inversion at 11q23 in infant acute myeloid leukemia fuses MLL to CALM, a gene that encodes a clathrin assembly protein. DR DS Wechsler, LD Engstrom, BM Alexander, DG Motto Genes Chromosomes Cancer 36 (1), 26-36, 2003 | 46 | 2003 |
| MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer LD Engstrom, R Aranda, L Waters, K Moya, V Bowcut, L Vegar, D Trinh, ... Cancer discovery 13 (11), 2412-2431, 2023 | 29 | 2023 |
| Mxi1-0, an alternatively transcribed Mxi1 isoform, is overexpressed in glioblastomas. DSW LD Engstrom, AS Youkilis, JL Gorelick, D Zheng, V Ackley, CA Petroff, LQ ... Neoplasia 6 (5), 660-73, 2004 | 28 | 2004 |
| PF-04449913, a small molecule inhibitor of Hedgehog signaling, is effective in inhibiting tumor growth in preclinical models AJ Jackson-Fisher, MJ McMahon, J Lam, C Li, LD Engstrom, K Tsaparikos, ... Cancer Research 71 (8_Supplement), 4504-4504, 2011 | 17 | 2011 |
| Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1G2032R … HY Zou, LR Engstrom, Q Li, M West Lu, RW Tang, H Wang, K Tsaparikos, ... Molecular Cancer Therapeutics 12 (11_Supplement), A277-A277, 2013 | 15 | 2013 |
| Mechanisms of acquired resistance to KRAS G12C inhibition in cancer. M Awad, S Liu, K Arbour, V Zhu, M Johnson, R Heist, T Patil, G Riely, ... Cancer Research 81 (13), 2021 | 12 | 2021 |
| Abstract LB-C09: The KRASG12C inhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination … DM Briere, A Calinisan, R Aranda, N Sudhakar, L Hargis, S Gatto, ... Molecular Cancer Therapeutics 18 (12_Supplement), LB-C09-LB-C09, 2019 | 11 | 2019 |
